RATIONALE: As the sole nitrogen donor in nitric oxide (NO) synthesis and key intermediate in the urea cycle, arginine and its metabolic pathways are integrally linked to cellular respiration, metabolism, and inflammation. OBJECTIVES: We hypothesized that arginine (Arg) bioavailability would be associated with airflow abnormalities and inflammation in subjects with asthma, and would be informative for asthma severity. METHODS: Arg bioavailability was assessed in subjects with severe and nonsevere asthma and healthy control subjects by determination of plasma Arg relative to its metabolic products, ornithine and citrulline, and relative to methylarginine inhibitors of NO synthases, and by serum arginase activity. Inflammatory parameters, including fraction of exhaled NO (Fe(NO)), IgE, skin test positivity to allergens, bronchoalveolar lavage, and blood eosinophils, were also evaluated. MEASUREMENTS AND MAIN RESULTS: Subjects with asthma had greater Arg bioavailability, but also increased Arg catabolism compared with healthy control subjects, as evidenced by higher levels of Fe(NO) and serum arginase activity. However, Arg bioavailability was positively associated with Fe(NO) only in healthy control subjects; Arg bioavailability was unrelated to Fe(NO) or other inflammatory parameters in severe or nonsevere asthma. Inflammatory parameters were related to airflow obstruction and reactivity in nonsevere asthma, but not in severe asthma. Conversely, Arg bioavailability was related to airflow obstruction in severe asthma, but not in nonsevere asthma. Modeling confirmed that measures of Arg bioavailabilty predict airflow obstruction only in severe asthma. CONCLUSIONS: Unlike Fe(NO), Arg bioavailability is not a surrogate measure of inflammation; however, Arg bioavailability is strongly associated with airflow abnormalities in severe asthma.
RATIONALE: As the sole nitrogendonor in nitric oxide (NO) synthesis and key intermediate in the urea cycle, arginine and its metabolic pathways are integrally linked to cellular respiration, metabolism, and inflammation. OBJECTIVES: We hypothesized that arginine (Arg) bioavailability would be associated with airflow abnormalities and inflammation in subjects with asthma, and would be informative for asthma severity. METHODS:Arg bioavailability was assessed in subjects with severe and nonsevere asthma and healthy control subjects by determination of plasma Arg relative to its metabolic products, ornithine and citrulline, and relative to methylarginine inhibitors of NO synthases, and by serum arginase activity. Inflammatory parameters, including fraction of exhaled NO (Fe(NO)), IgE, skin test positivity to allergens, bronchoalveolar lavage, and blood eosinophils, were also evaluated. MEASUREMENTS AND MAIN RESULTS: Subjects with asthma had greater Arg bioavailability, but also increased Arg catabolism compared with healthy control subjects, as evidenced by higher levels of Fe(NO) and serum arginase activity. However, Arg bioavailability was positively associated with Fe(NO) only in healthy control subjects; Arg bioavailability was unrelated to Fe(NO) or other inflammatory parameters in severe or nonsevere asthma. Inflammatory parameters were related to airflow obstruction and reactivity in nonsevere asthma, but not in severe asthma. Conversely, Arg bioavailability was related to airflow obstruction in severe asthma, but not in nonsevere asthma. Modeling confirmed that measures of Arg bioavailabilty predict airflow obstruction only in severe asthma. CONCLUSIONS: Unlike Fe(NO), Arg bioavailability is not a surrogate measure of inflammation; however, Arg bioavailability is strongly associated with airflow abnormalities in severe asthma.
Authors: Michela Silvestri; Federica Sabatini; Rosa Sale; Anna-Carla Defilippi; Laura Fregonese; Elena Battistini; Maurizio G Biraghi; Giovanni A Rossi Journal: Pediatr Pulmonol Date: 2003-05
Authors: S B Khatri; M Ozkan; K McCarthy; D Laskowski; J Hammel; R A Dweik; S C Erzurum Journal: Am J Respir Crit Care Med Date: 2001-11-15 Impact factor: 21.405
Authors: A C Olin; N Stenfors; K Torén; A Blomberg; R Helleday; M C Ledin; G Ljungkvist; A Ekman; T Sandström Journal: Respir Med Date: 2001-06 Impact factor: 3.415
Authors: Herman Meurs; Sue McKay; Harm Maarsingh; Marco A M Hamer; Lejla Macic; Niek Molendijk; Johan Zaagsma Journal: Br J Pharmacol Date: 2002-06 Impact factor: 8.739
Authors: Carrie V Breton; Hyang-Min Byun; Xinhui Wang; Muhammad T Salam; Kim Siegmund; Frank D Gilliland Journal: Am J Respir Crit Care Med Date: 2011-04-21 Impact factor: 21.405
Authors: Raed A Dweik; Peter B Boggs; Serpil C Erzurum; Charles G Irvin; Margaret W Leigh; Jon O Lundberg; Anna-Carin Olin; Alan L Plummer; D Robin Taylor Journal: Am J Respir Crit Care Med Date: 2011-09-01 Impact factor: 21.405
Authors: Claudia R Morris; David T Mauger; Jung H Suh; Wanda Phipatanakul; William J Sheehan; James N Moy; Ian M Paul; Stanley J Szefler; Daniel J Jackson; Anne M Fitzpatrick Journal: J Allergy Clin Immunol Date: 2018-03-05 Impact factor: 10.793
Authors: Michael S Gough; Mary Anne M Morgan; Cynthia M Mack; Denise C Darling; Lauren M Frasier; Kathleen P Doolin; Michael J Apostolakos; Judith C Stewart; Brian T Graves; Erland Arning; Teodoro Bottiglieri; Robert A Mooney; Mark W Frampton; Anthony P Pietropaoli Journal: Crit Care Med Date: 2011-06 Impact factor: 7.598
Authors: Ruby Fernandez-Boyanapalli; Elena Goleva; Christena Kolakowski; Elysia Min; Brian Day; Donald Y M Leung; David W H Riches; Donna L Bratton; E Rand Sutherland Journal: J Allergy Clin Immunol Date: 2012-11-13 Impact factor: 10.793
Authors: Fernando Holguin; Suzy A A Comhair; Stanley L Hazen; Robert W Powers; Sumita S Khatri; Eugene R Bleecker; William W Busse; William J Calhoun; Mario Castro; Anne M Fitzpatrick; Benjamin Gaston; Elliot Israel; Nizar N Jarjour; Wendy C Moore; Stephen P Peters; W Gerald Teague; Kian Fan Chung; Serpil C Erzurum; Sally E Wenzel Journal: Am J Respir Crit Care Med Date: 2012-11-29 Impact factor: 21.405